Cargando…
Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease
Invasive meningococcal disease occurs worldwide causing an estimated 50,000–135,000 deaths each year in addition to significant sequelae. In developed countries the disease is usually sporadic but outbreaks and epidemics, usually due to serogroups B and C, have occurred. In the US, an increasing num...
Autor principal: | Kimmel, Sanford R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621387/ https://www.ncbi.nlm.nih.gov/pubmed/19209256 |
Ejemplares similares
-
Co-administration of vaccines: a focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines
por: Bonanni, Paolo, et al.
Publicado: (2019) -
Meningococcal conjugate vaccines: optimizing global impact
por: Terranella, Andrew, et al.
Publicado: (2011) -
Factors contributing to the immunogenicity of meningococcal conjugate vaccines
por: Bröker, Michael, et al.
Publicado: (2016) -
Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023) -
The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: A randomized, controlled non-inferiority study
por: Dbaibo, Ghassan, et al.
Publicado: (2012)